To Choose the Best First-line Drug for CML, Consider Efficacy and CostSeptember 6, 2024CMLCLLBusiness of MedicinePatient & Survivor CareB Cell Lymphoma
Do Clonal Hematopoiesis and Mosaic Chromosomal Alterations Increase Solid Tumor Risk?September 6, 2024Patient & Survivor CareAggressive LymphomasALLAMLB Cell LymphomaCLLCML
Cancer Cases, Deaths in Men Predicted to Surge by 2050August 30, 2024Patient & Survivor CareMixed TopicsDLBCLAggressive LymphomasALLAMLB Cell Lymphoma
Patient Navigators for Serious Illnesses Can Now Bill Under New Medicare CodesAugust 27, 2024Business of MedicinePatient & Survivor Care
Cancer Treatment 101: A Primer for Non-OncologistsAugust 23, 2024DLBCLMixed TopicsPatient & Survivor CarePediatricsBusiness of MedicineAggressive LymphomasALL
When Childhood Cancer Survivors Face Sexual ChallengesAugust 22, 2024Mixed TopicsPediatricsPatient & Survivor CareALLCMLCLLHodgkin Lymphoma
FDA Approves Lymphir for R/R Cutaneous T-Cell LymphomaAugust 9, 2024T Cell LymphomasPatient & Survivor CareBusiness of Medicine
Immunotherapy May Be Overused in Dying Patients With CancerAugust 8, 2024DLBCLMixed TopicsPatient & Survivor CarePediatricsAggressive LymphomasALLAML
FDA Approves First Engineered Cell Therapy for a Solid TumorAugust 2, 2024Patient & Survivor CareBusiness of Medicine
FDA Expands Darzalex Faspro Indication in MyelomaAugust 2, 2024Multiple MyelomaPatient & Survivor CareBusiness of Medicine
The Last 30 Days: How Oncologists’ Choices Affect End-of-Life Cancer CareAugust 2, 2024Patient & Survivor CareDLBCLMixed Topics
Ancient Viruses in Our DNA Hold Clues to Cancer TreatmentAugust 2, 2024Patient & Survivor CareDLBCLMixed TopicsAggressive LymphomasALLAMLB Cell Lymphoma
FDA Calls AstraZeneca’s NSCLC Trial Design Into QuestionJuly 30, 2024Business of MedicinePatient & Survivor Care
Greater Transparency of Oncologists’ Pharma Relationships NeededJuly 22, 2024Patient & Survivor CareDLBCLDiversity in MedicineMixed TopicsAggressive LymphomasALLAML
